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ABSTRACT
Background. Carrier solutions play an important role in
the distribution, plasma absorption, chemical stability, and
solubility of anticancer agents during hyperthermic
intraperitoneal chemotherapy (HIPEC). In the current
study, lipophilic properties of carrier solutions were eval-
uated to determine whether they improved anticancer drug
absorption rates using mitomycin-C (MMC) or oxaliplatin
HIPEC as compared to hydrophilic carrier solutions.
Methods. Sprague-Dawley rats were divided into two
groups: MMC and oxaliplatin treatment groups. Each
group was then further subdivided by carrier solution:
Dianeal PD-2 peritoneal dialysis solution, 5% dextrose
solution and 20% lipid solution (Lipision). HIPEC was
performed over 60 min at 41–42 C using the anticancer
drugs MMC (35 mg/m2) or oxaliplatin (460 mg/m2). The
plasma area under the curve (AUC; AUCplasma), peritoneal
AUC (AUCperitoneum), and peritoneal/plasma AUC ratios
were compared among HIPEC carrier solutions.
Results. Plasma drug concentrations were significantly
different among carrier solutions, varying by time. In
contrast, peritoneal drug concentrations did not change
with carrier solution. In the MMC group, the peri-
toneal/plasma AUC ratio of a lipid solution was three times
higher than Dianeal (p\ 0.001). In the oxaliplatin group,
the peritoneal/plasma AUC ratio was significantly different
between carrier solutions (p = 0.046). Although the oxali-
platin AUCperitoneum did not vary (p = 0.941), the
AUCplasma of a lipid solution was lower than that of 5%
dextrose solution (p = 0.039).
Conclusions. The lipid carrier solution increases the
peritoneal/plasma AUC ratio and decreases plasma
absorption rates. However, further study is required before
clinical uses, considering its pharmacologic properties and
possible risks after HIPEC.
Hyperthermic intraperitoneal chemotherapy (HIPEC)
after cytoreductive surgery is utilized based on studies
showing that microscopic residual tumors can be eradi-
cated by intraperitoneally (IP)-administrated anticancer
drugs, with enhanced cytotoxic effect at 41–43 C.1,2 As IP
drug administration results in a high concentration gradient
in the peritoneal-plasma barriers, anticancer drugs can
infiltrate tumors following the principles of convection,
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diffusion, and recirculation, which is different from sys-
temic chemotherapy administration.1,3,4 High drug
concentration within the peritoneal cavity produces a
driving force for anticancer drugs to infiltrate tumor cells
during HIPEC.3 In addition, slow plasma absorption rates
of anticancer drugs enhance IP drug efficacy and reduce
systemic toxicities.5
Anticancer drug tissue penetration during HIPEC
depends on several pharmacologic properties, including
drug concentration, time of exposure, molecular weight
(MW), temperature, and lipophilicity.6 For optimal HIPEC
treatment, it is crucial to select the appropriate carrier
solution for each anticancer drug to enhance drug activity,
because pharmacologic properties are uniquely different
during use in the peritoneal cavity.6,7 Especially, carrier
solutions have an important role in the distribution, plasma
absorption, chemical stability, and solubility of anticancer
agents during HIPEC.8,9 Previous reports evaluated
hydrophilic carrier solution pharmacologic properties for
HIPEC.6,10–12 In the current study, the ability of lipophilic
carrier solutions to improve the absorption rate of anti-
cancer drugs during HIPEC was determined. In addition,
the pharmacologic characteristics of mitomycin C (MMC)
and oxaliplatin were evaluated according to HIPEC carrier
solution to find the optimal pharmacologic conditions to
treat patients with colorectal cancer carcinomatosis.
METHODS
Experimental Design
According to anticancer treatment, animals were divided
into two groups: MMC or oxaliplatin HIPEC. Three carrier
solutions were evaluated in this study: Dianeal PD-2
1.5% peritoneal dialysis solution (Baxter, USA), 5% dex-
trose solution, and 20% lipid solution (Lipision, JW
Pharmaceutical, Republic of Korea). Three rats were used
to perform HIPEC for each carrier solution. The Animal
Research Committee of Ajou University, Republic of
Korea (IACUC Number 2016-0029) approved the study
protocol. Experiments were performed at the Laboratory
Animal Research Center at Ajou University Medical
Center, Suwon, Korea.
Animals
Fifteen, 8-week-old, male Sprague-Dawley rats,
weighing 290–320 g, were purchased from Orientbio Inc.
(Kyunggi-do, Korea). Mean body surface area (BSA) was
calculated by using the Du Bois method.13 Rats were
housed in filter-top cages for 1 week before experiments
with free access to food and water (Ziegler lab animal
diet, USA). The animal laboratory was kept under standard
conditions with temperature 21–24 C, humidity 40–60%,
12-h light cycle, and filtered air. A total of 15 rats, com-
prising 3 rats per group, was used in this study.
Experimental Settings for HIPEC
The HIPEC experimental equipment was setup as shown
in Fig. 1. The inflow line was inserted into the roller of a
peristaltic pump (Masterflex C/L pump, Bernant, USA)
and delivered HIPEC solutions at a flow rate of 40 mL/
min. The outflow line connected the abdominal cavity to a
reservoir chamber. Outflow line circulating fluids could be
returned to the reservoir chamber using negative pressure
induced by suction. The temperature of circulating HIPEC
solutions was maintained at 41–42 C. Both inflow and
outflow lines were heated by a circulating warm bath
(Lauda E100, Lauda, Germany). Three sites were moni-
tored for consistent temperature using thermometers:
circulating HIPEC solutions in the rat abdominal cavity
and rectum, and the heated water in the warm bath.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Procedure
All animals received general inhalation anesthesia using
3% isoflurane with 1:1 oxygen and nitrous oxide before
HIPEC procedures. Before the anesthesia, 20 mL of water
was given orally to all rats to prevent dehydration.
According to the Coliseum technique, a 4- to 5-cm medial
longitudinal incision was made in the rat abdominal wall.14
Then, all margins of the abdominal wall were elevated and
fixed in the acryl plates, which were located 15-cm above
the basal plate. After setting the HIPEC equipment as
described in Fig. 1, HIPEC solutions were prepared with
MMC (35 mg/m2) or oxaliplatin of (460 mg/m2), which
were mixed with 300 mL of carrier solution. Blood and
peritoneal fluid samples were collected at 0 (starting time),
5, 10, 20, 30, 45, and 60 min after beginning HIPEC.
Peritoneal fluid was collected in the HIPEC circulated fluid
of the abdominal cavity, and blood samples were collected
from the retro-orbital venous sinus after inhalation anes-
thesia. All samples were kept frozen at - 60 C until
further analyses.
Sample Preparation and Analytical Methods
Samples were thawed at room temperature before ana-
lyzing drug concentration. Protein precipitation was
performed to remove blood and peritoneal components. For
MMC analysis, samples were centrifuged at 15,000 rpm at
4 C for 15 min. Then, 75 lL of the supernatant was
diluted with 90% acetonitrile (300 lL). After vortex
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shaking for 10 min at room temperature, samples were
centrifuged again at 15,000 rpm, 4 C for 15 min. After
removing the organic solvent layer and precipitated pro-
teins, supernatants were leached with a 0.2-lm syringe
filter. The filtered supernatants were then analyzed by
tandem mass spectrometry (Agilent 6490 QQQ Triple
Quadrupole LC/MS System, Agilent Technologies, Santa
Clara, CA) to measure MMC drug concentrations.
Oxaliplatin solutions were analyzed by inductively
coupled plasma-quadrupole mass spectrometry (ICP-QMS;
NexION 300D, PerkinElmer, US). To measure platinum
complex in the oxaliplatin, samples were prepared using a
microwave digestion system. Samples were placed in
Teflon vessels with 5 mL of HNO3 and digested in a
microwave oven at 800 W for 1 h. After diluting to 25 mL
with distilled water, samples were analyzed by ICP-QMS.
Statistical Analyses
Statistical analyses were performed using SPSS 23
(SPSS Inc., Chicago, IL), SAS 9.3 (SAS Institute Inc.,
Cary, NC), and R 3.4.1 software (The R Foundation for
Statistical Computing). Linear mixed models were used to
compare drug concentrations between carrier solutions
according to time. The independent t test and one-way
analysis of variance (ANOVA) were used to compare area
under the curve (AUC) ratios among carrier solutions.
Post-hoc analyses were performed using the Scheffe cor-
rection method. A p value\ 0.05 was considered
statistically significant.
RESULTS
Comparison of Drug Concentrations over Time During
HIPEC
In the MMC group, the plasma drug concentration in the
Dianeal group was increased compared to the lipid
solution over time, as shown in Table 1 and Fig. 2a.
However, MMC concentrations in the peritoneal fluid were
not significantly different between Dianeal and lipid
solutions (p = 0.2313).
In the oxaliplatin group, the plasma drug concentrations
were significantly different among the carrier solutions by
time (p = 0.0049). The plasma absorption rate was highest
in the oxaliplatin mixed with 5% dextrose solution group
(Fig. 2c). However, oxaliplatin concentrations in the peri-
toneal fluid were not significantly different among the
carrier solutions (Table 1).
Comparison of AUC Ratios Between Water and Lipid
Solutions
In the MMC group, the AUC of the peritoneal fluid
(AUCperitoneum) was higher in the lipid carrier solution than
Dianeal. Conversely, the AUC of the plasma (AUCplasma)
was lower in the lipid solution compared to Dianeal.
Thus, the peritoneal/plasma AUC ratio of the lipid carrier
solution was approximately three times higher than Dia-
neal in the MMC group (p\ 0.001; Table 2).
In the oxaliplatin group, the AUCperitoneum was not sig-
nificantly different among the carrier solutions (p = 0.941).
However, the AUCplasma of the 5% dextrose solution was
Thermometer
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FIG. 1 HIPEC rat model
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higher than that of the lipid solution (p = 0.039). There was
no significant difference in the AUCplasma between the 5%
dextrose solution and Dianeal (p = 0.070). The oxali-
platin AUC ratio was different among the carrier solutions.
In particular, the oxaliplatin AUC ratio in the lipid solution
was marginally higher than that of the 5% dextrose solution
during HIPEC (p = 0.056). According to AUC ratios of
oxaliplatin, which were cut off at 30 min, AUC ratio of
lipid solution was higher than 5% dextrose solution (Sup-
plementary Table 1).
Plasma Drug Concentration Gradient by Carrier
Solution
To estimate the changes in plasma drug concentration
among the carrier solutions, the plasma concentration
gradient of anticancer drugs was calculated using a linear
mixed model, according to time. As shown in Table 3, the
estimated plasma concentration gradient of MMC had a
steeper slope with Dianeal compared with the lipid solu-
tion. On the other hand, the estimated plasma concentration
gradient of oxaliplatin had a steeper slope in the 5% dextrose
solution compared to both the Dianeal and the lipid solution
(p\ 0.001). However, there was no significant difference in
the oxaliplatin estimated plasma concentration gradient
between the Dianeal and lipid solutions.
DISCUSSION
HIPEC has pharmacologic principles that provide
regionally intensified antineoplastic drug concentration in
the peritoneal cavity and promote tumor cell penetration
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FIG. 2 Concentrations of mitomycin-C (MMC) and oxaliplatin by
HIPEC carrier solution. The concentration of MMC in plasma (a) and
in the peritoneal fluid (b). The concentration of oxaliplatin in the
plasma (c) and in the peritoneal fluid (d). CMMC, concentration of
MMC; Coxaliplatin, concentration of oxaliplatin
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with a prolonged presence in the peritoneal-plasma bar-
rier.3 Based on the anatomical structures of the
peritoneum, anticancer drugs that have large MW and
water insolubility are correlated with a larger AUC ratio
and longer stay in the peritoneal cavity.1 The intercellular
gaps of the mesothelium are larger than those in the
endothelium; therefore, large molecules that cannot pass
through endothelial layers do penetrate mesothelial layers.
The MW of MMC is 334.3 g/mol and that of oxaliplatin is
397.3 g/mol, both smaller than anticancer drugs paclitaxel
(MW = 853.9 g/mol) and docetaxel (MW = 861.9
g/mol).4 In addition, the logarithm ratio of partition coef-
ficient (log P) of MMC is - 1.6 and oxaliplatin is - 0.47,
which tends to be water-soluble. Therefore, these phar-
macologic characteristics of both MMC and oxaliplatin are
not inherently suitable to enhance the effect of IP
chemotherapy, with the exception of water solubility,
which is a useful characteristic to circulate solutes during
HIPEC.
However, importantly, our results demonstrate that the
use of a lipid carrier solution increased the AUC ratio and
reduced the plasma absorption rate. Although the oxali-
platin AUCperitoneum was not significantly different among
carrier solutions, our data showed that a lipid carrier
solution has advantages, controlling the permeability of
endothelial layers and reducing the plasma absorption rate
during HIPEC. This could be a result of hydrophobic lipid
particles that are resistant to traversing the plasma mem-
brane of endothelial cell layers.
In HIPEC treatment of colorectal cancer patients with
peritoneal carcinomatosis, both MMC and oxaliplatin are
used. The MMC carrier solution currently used in most
HIPEC centers is an isotonic solution.15 Therefore, in this
study, we compared the effects of carrier solutions except
5% dextrose solution in the MMC HIPEC. However, the
optimal selection of carrier solution during oxaliplatin
HIPEC is still debated, as oxaliplatin can be degraded in
chloride-containing carrier solutions, because the oxalate
ligand of oxaliplatin can be substituted into chloride ions.12
Elias et al.16 reported favorable oncological outcomes
using oxaliplatin with 5% dextrose carrier solution. How-
ever, it has been reported that the hypotonicity of the
dextrose solution increases the risk of postoperative com-
plications after HIPEC, such as severe electrolyte
imbalance, hyperglycemia, tissue edema, and intraperi-
toneal hemorrhagic complications.10,17–19 Therefore, in the
current study, we compared the oxaliplatin AUC ratios
among three carrier solutions: 5% dextrose solution, Dia-
neal, and lipid solution to compare lipophilicity versus
hydrophilicity and chloride-containing versus non-chlo-
ride-containing solutions.
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According to the comparison of carrier solutions
between lipophilicity and hydrophilicity, the oxaliplatin
AUCperitoneum was not significantly different among carrier
solutions. However, the AUCplasma of the lipid solution was
lower than that of the 5% dextrose solution. In addition, the
AUC ratio in the lipid solution was marginally higher than
hydrophilic carrier solution in both oxaliplatin and MMC
HIPEC. Thus, in this study, the lipophilicity of a carrier
solution seemed to have an advantage in reducing plasma
absorption and increasing the AUC ratio compared with
hydrophilic carrier solutions.
In HIPEC using oxaliplatin, 30-min duration is regarded
as clinically suitable considering half-life of oxaliplatin and
systemic toxicities.20 However, because this study was the
first experiment to use a lipophilic carrier solution for
oxaliplatin-HIPEC, HIPEC was performed to evaluate fully
pharmacologic properties of lipid carrier solution until
60 min. The AUC ratio of oxaliplatin in the lipid solution
was higher than 5% dextrose solution at both 30 and 60 min.
Compared with the pharmacological effects of oxali-
platin in the chloride-containing solutions, our results
support the effectiveness of Dianeal. The chloride con-
centration of Dianeal is 96 mmol/L, whereas that for 5%
dextrose solution is 0 mmol/L. Lipision is composed of
purified soybean oil, purified phospholipid, and glycerin.
As demonstrated in Table 2, Dianeal exhibited advan-
tages to reducing plasma absorption of anticancer drugs,
compared with 5% dextrose solution, when performing
oxaliplatin HIPEC. In addition, structural instability of
oxaliplatin in the chloride-containing solutions during
HIPEC could be acceptable, as a previous report by Mehta
et al.12,21 indicated that the degradation rates of oxaliplatin
is limited within 10–15% in the chloride-containing HIPEC
carrier solution. It is also expected that peritoneal dialysis
solutions such a Dianeal can have advantages to reduce
postoperative complications, such as electrolyte imbalance
and metabolic disturbance.
Our study results also showed that the AUC ratio of a
lipid carrier solution was larger than other carrier solutions.
However, there are some limitations in using lipid carrier
solutions in clinical applications for HIPEC. Lipision,
which was used in this study, is a fat emulsion. Although
the lipid layers of Lipision retard plasma absorption rates
of anticancer drugs during HIPEC, the hypertonicity and
electrical resistance of these lipid layers can inhibit the
permeability of peritoneal-plasma barriers. In addition,
according to the pharmacokinetic principles of HIPEC,
longer duration in the peritoneum delays recirculation of
the tumor core.1 Because the efficacy of HIPEC is related
to sustained peritoneal drug concentrations, as well as drug
infiltration into the tumor core, this contrary phenomenon
should be considered in selecting an optimal IP
chemotherapeutic agent. In our results, although the lipid
carrier solution prolonged peritoneal occupancy, as well as
reduced plasma absorption rate, the hydrophobicity of the
lipid solution might be inadequate to recirculate into tumor
core from the capillary vessels and to increase cytotoxicity.
Furthermore, because the bioavailability of anticancer
agents is assessed from the release rate of an entrapped
drug in lipid layers, it can be questioned whether anticancer
agents mixed in a lipid carrier solution have complete
tumor cell cytotoxicity during HIPEC.3,22,23 The release
rate of anticancer drugs in the lymphatic channels and the
risk of fat embolism are also to be considered when a lipid
carrier solution is used during HIPEC.
This study has several limitations, including a small
sample-sized experiment in the animal model. In addition,
there is a lack of investigation into both the cytotoxic
effects and the rate of lymphatic spread of anticancer drugs
during HIPEC with a lipophilic carrier solution. Naı¨ve
oxaliplatin is known to have less cytotoxicity than
dichloro-platinum compound Pt(dach)Cl2, which is an
active form that is transformed in chloride-containing
media.24,25 Because our study measured platinum
TABLE 3 Estimated formulas for the anticancer drug concentration in the plasma
Anticancer drugs Carrier solutions Estimated formulas of the graph
for the plasma drug concentrations
(MMC: Fig. 2a, oxaliplatin: Fig. 2c)
Estimated concentration
gradient (SE)
p value
Mitomycin-C Dianeal Cplasma = 3.05  time ? 30.99 3.05 (0.21) \ 0.0001
Lipid solution Cplasma = 0.74  time ? 27.80 0.74 (0.23)
Oxaliplatin Dianeal Cplasma = 59.15  time - 126.21 59.15 (7.52) \ 0.0001
(Dianeal vs. 5DW, p\ 0.001;
Dianeal vs. lipid, p = 0.3957;
5DW vs. lipid, p\ 0.001)
5% dextrose solution Cplasma = 113.21  time - 57.74 113.21 (7.35)
Lipid solution Cplasma = 43.05  time ? 14.56 43.05 (7.35)
Estimated formulas was calculated by random intercept model
Bold values are statistically significant (p\ 0.05)
Cplasma, concentration of plasma; SE, standard error; 5DW, 5% dextrose
Calculated by linear mixed model
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concentration of oxaliplatin, further studies are required to
measure the concentration of oxaliplatin transformation to
understand both structural instability and cytotoxicity of
oxaliplatin depending on different HIPEC carrier solutions.
CONCLUSIONS
A lipid carrier solution is promising, because it increases
the AUC ratio and decreases plasma absorption during
HIPEC. However, 5% dextrose solution is inferior to both
Dianeal and lipid solutions as an oxaliplatin-based HIPEC
carrier solution. The choice between Dianeal and lipid
solutions should be made based on considerations of safety
and further data regarding the actual efficacy of cytotoxic
agents in these solutions.
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